-
Antibody evasion associated with the RBD significant mutations in several emerging SARS-CoV-2 variants and its subvariants Drug Resist. Updat. (IF 24.3) Pub Date : 2023-09-22 Manojit Bhattacharya, Srijan Chatterjee, Sang-Soo Lee, Kuldeep Dhama, Chiranjib Chakraborty
Since the origin of the wild strain of SARS-CoV-2, several variants have emerged, which were designated as VOC, VOI, and VUM from time to time. The Omicron variant is noted as the recent VOC. After the origin of the Omicron variant on November 2021, several subvariants of Omicron have originated subsequently, like BA.1/2, BA.2.75/2.75.2, BA.4/5, BF.7, BQ.1/1.1, XBB.1/1.5, etc. which are circulated
-
Effective targeting of breast cancer by the inhibition of P-glycoprotein mediated removal of toxic lipid peroxidation byproducts from drug tolerant persister cells Drug Resist. Updat. (IF 24.3) Pub Date : 2023-09-17 Kornélia Szebényi, András Füredi, Eszter Bajtai, Sai Nagender Sama, Agnes Csiszar, Balázs Gombos, Pál Szabó, Michael Grusch, Gergely Szakács
Therapy resistance has long been considered to occur through the selection of pre-existing clones equipped to survive and quickly regrow, or through the acquisition of mutations during chemotherapy. Here we show that following in vitro treatment by chemotherapy, epithelial breast cancer cells adopt a transient drug tolerant phenotype characterized by cell cycle arrest, epithelial-to-mesenchymal transition
-
The definition and global epidemiology of nonmobile colistin resistance (NMCR-3) determinants in Aeromonas from 1968 to 2022 Drug Resist. Updat. (IF 24.3) Pub Date : 2023-09-07 Keyi Yu, Zhenzhou Huang, Yue Xiao, Xuemei Bai, He Gao, Duochun Wang
Polymyxins are the last line of defense in infections caused by multidrug-resistant Gram-negative bacteria. The chromosomal EptA in Aeromonas genus was defined as a nonmobile colistin resistance determinant 3 (NMCR-3). A total of 14 NMCR-3 genotypes were identified. The global prevalence of Aeromonas-borne NMCRs and MCRs indicates an increasing trend from 1968 to 2022. And an index of resistance risk
-
CircPTEN suppresses human clear cell renal carcinoma progression and resistance to mTOR inhibitors by targeting epigenetic modification Drug Resist. Updat. (IF 24.3) Pub Date : 2023-09-02 Yangyang Zhan, Yang Liu, Rui Yang, Qiong Chen, Fei Teng, Yueying Huang, Xin Jiang, Yueming Wang, Bin Yu, Ding Zhang, Leilei Bao, Xinli Liu, Jiwei Huang
Renal cell carcinoma (RCC) is known to be the most commonly diagnosed kidney cancer. Clear cell RCC (ccRCC) represents approximately 85% of diagnosed RCC cases. Targeted therapeutics, such as multi-targeted tyrosine kinase inhibitors (TKI) and mTOR inhibitors, are widely used in ccRCC therapy. However, patients treated with mTOR and TKI inhibitors easily acquire drug resistance, making the therapy
-
Treatment Strategies and Drug Resistance Mechanisms in Adenocarcinoma of Different Organs Drug Resist. Updat. (IF 24.3) Pub Date : 2023-08-22 Peng Xing, Shuo Wang, Yu Cao, Bo Liu, Feifei Zheng, Wei Guo, Junhao Huang, Zimo Zhao, Ziyi Yang, Xingda Lin, Liang Sang, Zhe Liu
Adenocarcinoma is a common type of malignant tumor, originating from glandular epithelial cells in various organs, such as pancreas, breast, lung, stomach, colon, rectus, and prostate. For patients who lose the opportunity for radical surgery, medication is available to provide potential clinical benefits. However, drug resistance is a big obstacle to obtain desired clinical prognosis. In this review
-
Natural medicinal compounds target signal transduction pathways to overcome ABC drug efflux transporter-mediated multidrug resistance in cancer Drug Resist. Updat. (IF 24.3) Pub Date : 2023-08-21 Pradhapsingh Bharathiraja, Priya Yadav, Andaleeb Sajid, Suresh V. Ambudkar, N. Rajendra Prasad
ATP-binding cassette (ABC) transporters such as ABCB1, ABCG2, and ABCC1 are the major players in drug efflux-mediated multidrug resistance (MDR), which severely affects the efficacy of chemotherapy. Several synthetic compounds block the drug transport by ABC transporters; however, they exhibit a narrow therapeutic window, and produce side effects in non-target normal tissues. Conversely, the downregulation
-
Cell membrane-camouflaged bufalin targets NOD2 and overcomes multidrug resistance in pancreatic cancer Drug Resist. Updat. (IF 24.3) Pub Date : 2023-08-21 Wei Zhang, Yibao Fan, Jinze Zhang, Dan Shi, Jiahui Yuan, Milad Ashrafizadeh, Wei Li, Man Hu, A.M. Abd El-Aty, Ahmet Hacimuftuoglu, Michael Linnebacher, Yongxian Cheng, Weiguang Li, Shuo Fang, Peng Gong, Xianbin Zhang
Aims Multidrug resistance in pancreatic cancer poses a significant challenge in clinical treatment. Bufalin (BA), a compound found in secretions from the glands of toads, may help overcome this problem. However, severe cardiotoxicity thus far has hindered its clinical application. Hence, the present study aimed to develop a cell membrane-camouflaged and BA-loaded polylactic-co-glycolic acid nanoparticle
-
H3K4me3 remodeling induced acquired resistance through O-GlcNAc transferase Drug Resist. Updat. (IF 24.3) Pub Date : 2023-08-10 Dinoop Ravindran Menon, Heinz Hammerlindl, Gregory Gimenez, Sabrina Hammerlindl, Elmar Zuegner, Joachim Torrano, Natalie Bordag, Abdullah Al Emran, Maybelline Giam, Simon Denil, Norman Pavelka, Aik-Choon Tan, Richard A. Sturm, Nikolas K. Haass, Giulia Rancati, Meenhard Herlyn, Christoph Magnes, Michael R. Eccles, Mayumi Fujita, Helmut Schaider
Aims Drivers of the drug tolerant proliferative persister (DTPP) state have not been well investigated. Histone H3 lysine-4 trimethylation (H3K4me3), an active histone mark, might enable slow cycling drug tolerant persisters (DTP) to regain proliferative capacity. This study aimed to determine H3K4me3 transcriptionally active sites identifying a key regulator of DTPPs. Methods Deploying a model of
-
Structure, function, and inhibition of catalytically asymmetric ABC transporters: Lessons from the PDR subfamily Drug Resist. Updat. (IF 24.3) Pub Date : 2023-08-05 Atanu Banerjee, Jorgaq Pata, Vincent Chaptal, Ahcène Boumendjel, Pierre Falson, Rajendra Prasad
ATP-binding cassette (ABC) superfamily comprises a large group of ubiquitous transmembrane proteins that play a crucial role in transporting a diverse spectrum of substrates across cellular membranes. They participate in a wide array of physiological and pathological processes including nutrient uptake, antigen presentation, toxin elimination, and drug resistance in cancer and microbial cells. ABC
-
Analysis of SARS-CoV-2 mutations associated with resistance to therapeutic monoclonal antibodies that emerge after treatment Drug Resist. Updat. (IF 24.3) Pub Date : 2023-07-31 Daniele Focosi, Scott McConnell, David J. Sullivan, Arturo Casadevall
The mutation rate of the Omicron sublineage has led to baseline resistance against all previously authorized anti-Spike monoclonal antibodies (mAbs). Nevertheless, in case more antiviral mAbs will be authorized in the future, it is relevant to understand how frequently treatment-emergent resistance has emerged so far, under different combinations and in different patient subgroups. We report the results
-
NR5A2/HSD3B1 pathway promotes cellular resistance to second-generation antiandrogen darolutamide Drug Resist. Updat. (IF 24.3) Pub Date : 2023-07-17
This study investigated cellular mechanisms in steroidogenesis responsible for treatment resistance to the novel antiandrogen agent darolutamide in prostate cancer. HSD3B1 was overexpressed in darolutamide-resistant cells and induced by darolutamide treatment and AR knockdown. Inversely, HSD3B1 knockdown increased cellular sensitivity to darolutamide. Similarly, its upstream regulator NR5A2 was up-regulated
-
Identification of TMexCD-TOprJ-producing carbapenem-resistant Gram-negative bacteria from hospital sewage Drug Resist. Updat. (IF 24.3) Pub Date : 2023-07-13 Jie Zhu, Jingnan Lv, Zhichen Zhu, Tao Wang, Xiaofang Xie, Haifang Zhang, Liang Chen, Hong Du
Carbapenems and tigecycline are crucial antimicrobials for the treatment of gram-negative bacteria infections. Recently, a novel resistance-nodulation-division (RND) efflux pump gene cluster, tmexCD-toprJ, which confers resistance to tigecycline, has been discovered in animals and clinical isolates. It was reported that hospital sewage could act as a reservoir for gram-negative bacteria with high antimicrobial
-
New emerging SARS-CoV-2 variants and antiviral agents Drug Resist. Updat. (IF 24.3) Pub Date : 2023-06-26 A. Vitiello, A. Zovi, G. Rezza
Abstract not available
-
Purinergic signalling in cancer therapeutic resistance: From mechanisms to targeting strategies Drug Resist. Updat. (IF 24.3) Pub Date : 2023-06-28 Wenhui Jia, Zhao Huang, Li Zhou, Yih-Cherng Liou, Francesco Di Virgilio, Henning Ulrich, Peter Illes, Wei Zhang, Canhua Huang, Yong Tang
Purinergic signalling, consisting of extracellular purines and purinergic receptors, modulates cell proliferation, invasion and immunological reaction during cancer progression. Here, we focus on current evidence that suggests the crucial role of purinergic signalling in mediating cancer therapeutic resistance, the major obstacle in cancer treatment. Mechanistically, purinergic signalling can modulate
-
Elevated NOX4 promotes tumorigenesis and acquired EGFR-TKIs resistance via enhancing IL-8/PD-L1 signaling in NSCLC Drug Resist. Updat. (IF 24.3) Pub Date : 2023-06-22 Wen-Jing Liu, Lin Wang, Feng-Mei Zhou, Shu-Wen Liu, Wei Wang, Er-Jiang Zhao, Quan-Jun Yao, Wei Li, Yan-Qiu Zhao, Zhi Shi, Jian-Ge Qiu, Bing-Hua Jiang
-
Inhibition of phosphoglycerate dehydrogenase induces ferroptosis and overcomes enzalutamide resistance in castration-resistant prostate cancer cells Drug Resist. Updat. (IF 24.3) Pub Date : 2023-06-14 Jinxiang Wang, Leli Zeng, Nisha Wu, Yanling Liang, Jie Jin, Mingming Fan, Xiaoju Lai, Zhe-Sheng Chen, Yihang Pan, Fangyin Zeng, Fan Deng
-
Fighting drug-resistant lung cancer by induction of NAD(P)H:quinone oxidoreductase 1 (NQO1)-mediated ferroptosis Drug Resist. Updat. (IF 24.3) Pub Date : 2023-06-02 Jie Yu, Bingling Zhong, Lin Zhao, Ying Hou, Nana Ai, Jin-Jian Lu, Wei Ge, Xiuping Chen
-
Multi-omics dissection of stage-specific artemisinin tolerance mechanisms in Kelch13-mutant Plasmodium falciparum Drug Resist. Updat. (IF 24.3) Pub Date : 2023-06-02 Jiayun Chen, Peng Gao, Wei Xiao, Guangqing Cheng, Sanjeev Krishna, Jianyou Wang, Yin Kwan Wong, Chen Wang, Liwei Gu, Dong Hua Yang, Jigang Wang
Aims We investigated the stage-specific mechanisms of partial resistance to artemisinin (ART, an antimalarial drug) in Plasmodium falciparum (P. falciparum) carrying the Kelch13 C580Y mutation. Methods Using fluorescence labeling and activity-based protein profiling, we systematically profile the ART activation levels in P. falciparum during the entire intra-erythrocytic developmental cycle (IDC),
-
Targeting ACYP1-mediated glycolysis reverses lenvatinib resistance and restricts hepatocellular carcinoma progression Drug Resist. Updat. (IF 24.3) Pub Date : 2023-05-16 Shuai Wang, Lingyi Zhou, Ning Ji, Chengtao Sun, Linlin Sun, Jiao Sun, Yawei Du, Ningning Zhang, Yueguo Li, Weishuai Liu, Wei Lu
-
lncRNA SYTL5-OT4 promotes vessel co-option by inhibiting the autophagic degradation of ASCT2 Drug Resist. Updat. (IF 24.3) Pub Date : 2023-05-13 Qing Wen, Maohua Huang, Jingwen Xie, Runyu Liu, Qun Miao, Jinjun Huang, Junqiu Zhang, Wenyu lyu, Ming Qi, Chunyi Wu, Qi Qi, Zhijing Zhang, Rong Deng, Chenran Wang, Zhe-Sheng Chen, Dongmei Zhang, Wencai Ye, Minfeng Chen
Aims Vessel co-option is responsible for tumor resistance to antiangiogenic therapies (AATs) in patients with colorectal cancer liver metastasis (CRCLM). However, the mechanisms underlying vessel co-option remain largely unknown. Herein, we investigated the roles of a novel lncRNA SYTL5-OT4 and Alanine-Serine-Cysteine Transporter 2 (ASCT2) in vessel co-option-mediated AAT resistance. Methods SYTL5-OT4
-
GATA3 mediates doxorubicin resistance by inhibiting CYB5R2-catalyzed iron reduction in breast cancer cells Drug Resist. Updat. (IF 24.3) Pub Date : 2023-05-09 Zhen Zhu, Hongyu Shen, Jialin Xu, Zheng Fang, Guanqun Wo, Ying Ma, Kai Yang, Yalin Wang, Qiang Yu, Jin-hai Tang
Aims Neoadjuvant chemotherapy (NAC) is the primary preoperative therapy for breast cancer. The luminal subtype of breast cancer shows less NAC response than the basal subtype, with an inefficient NAC treatment effect. Understanding of the molecular and cellular mechanisms responsible for this chemoresistance is an important issue when determining optimal treatment. Methods Doxorubicin-induced apoptosis
-
Overexpression of blaGES-1 due to a strong promoter in the class 1 integron contributes to decreased ceftazidime-avibactam susceptibility in carbapenem-resistant Pseudomonas aeruginosa ST235 Drug Resist. Updat. (IF 24.3) Pub Date : 2023-05-02 Xi Li, Xiaofan Zhang, Heng Cai, Yiwei Zhu, Jingshu Ji, Tingting Qu, Yuexing Tu, Hua Zhou, Yunsong Yu
Sequence type 235 (ST235) Pseudomonas aeruginosa, harboring so-called international, high-risk, or widespread clones, is associated with relatively high morbidity and mortality, partly due to multiantibiotic and high-level antibiotic resistance. Treatment of infections caused by such strains with ceftazidime-avibactam (CZA) is often successful. However, CZA resistance in carbapenem-resistant P. aeruginosa
-
-
Targeting Myc-driven stress addiction in colorectal cancer Drug Resist. Updat. (IF 24.3) Pub Date : 2023-04-20 Haris Saeed, Brian J. Leibowitz, Lin Zhang, Jian Yu
MYC is a proto-oncogene that encodes a powerful regulator of transcription and cellular programs essential for normal development, as well as the growth and survival of various types of cancer cells. MYC rearrangement and amplification is a common cause of hematologic malignancies. In epithelial cancers such as colorectal cancer, genetic alterations in MYC are rare. Activation of Wnt, ERK/MAPK, and
-
Current therapy and drug resistance in metastatic castration-resistant prostate cancer Drug Resist. Updat. (IF 24.3) Pub Date : 2023-04-14 Maoping Cai, Xian-Lu Song, Xin-An Li, Mingkun Chen, Jiading Guo, Dong-Hua Yang, Zhanghui Chen, Shan-Chao Zhao
Castration-resistant prostate cancer (CRPC), especially metastatic castration-resistant prostate cancer (mCRPC) is one of the most prevalent malignancies and main cause of cancer-related death among men in the world. In addition, it is very difficult for clinical treatment because of the natural or acquired drug resistance of CRPC. Mechanisms of drug resistance are extremely complicated and how to
-
Pyrazinamide-resistant Tuberculosis Obscured From Common Targeted Molecular Diagnostics Drug Resist. Updat. (IF 24.3) Pub Date : 2023-04-06 Samuel J. Modlin, Mikael Mansjö, Jim Werngren, Chidera M. Ejike, Sven E. Hoffner, Faramarz Valafar
Here, we describe a clinical case of pyrazinamide-resistant (PZA-R) tuberculosis (TB) reported as PZA-susceptible (PZA-S) by common molecular diagnostics. Phenotypic susceptibility testing (pDST) indicated PZA-R TB. Targeted Sanger sequencing reported wild-type PncA, indicating PZA-S TB. Whole Genome Sequencing (WGS) by PacBio and IonTorrent both detected deletion of a large portion of pncA, indicating
-
Cancer-associated fibroblasts suppress ferroptosis and induce gemcitabine resistance in pancreatic cancer cells by secreting exosome-derived ACSL4-targeting miRNAs Drug Resist. Updat. (IF 24.3) Pub Date : 2023-03-28 Ran Qi, Yixuan Bai, Kun Li, Nanbin Liu, Yan Xu, Emre Dal, Yufeng Wang, Rui Lin, Hui Wang, Zhongyan Liu, Xinbo Li, Xiuyan Wang, Baomin Shi
Background Pancreatic cancer continues to be one of the world's most lethal cancers. Chemotherapy resistance in patients with advanced pancreatic cancer often accompany with dismal prognosis, highlighting the need to investigate mechanisms of drug resistance and develop therapies to overcome chemoresistance. Methods This research was filed with the Chinese Clinical Trial Registry (ChiCTR2200061320)
-
Collateral sensitivity between tetracyclines and aminoglycosides constrains resistance evolution in carbapenem-resistant Klebsiella pneumoniae Drug Resist. Updat. (IF 24.3) Pub Date : 2023-03-27 Xinqian Ma, Wen Xi, Deqing Yang, Lili Zhao, Wenyi Yu, Yukun He, Wentao Ni, Zhancheng Gao
Aims The acquisition of resistance to one antibiotic may confer an increased sensitivity to another antibiotic in bacteria, which is an evolutionary trade-off between different resistance mechanisms, defined as collateral sensitivity (CS). Exploiting the role of CS in treatment design could be an effective method to suppress or even reverse resistance evolution. Methods Using experimental evolution
-
The heterogeneous transition state of resistance to RET kinase inhibitors converges on ERK1/2-driven Aurora A/B kinases Drug Resist. Updat. (IF 24.3) Pub Date : 2023-03-24 Xueqing Hu, Xuan Liu, Ujjwol Khatri, Jie Wu
Aim While most patients with RET-altered cancer responded to the RET protein tyrosine kinase inhibitors (TKIs) pralsetinib (BLU667) and selpercatinib (LOXO292), few achieved a complete response. Heterogeneity in residual tumors makes it difficult to target their diverse genetic alterations individually. The aim of this study is to characterize the cancer cells that persist under continuous RET TKI
-
A phosphoglycerate mutase 1 allosteric inhibitor overcomes drug resistance to EGFR-targeted therapy via disrupting IL-6/JAK2/STAT3 signaling pathway in lung adenocarcinoma Drug Resist. Updat. (IF 24.3) Pub Date : 2023-03-16 Qian Liang, Miaomiao Gong, Jing-Hua Zou, Ming-yu Luo, Lu-lu Jiang, Cheng Wang, Ning-xiang Shen, Mo-cong Zhang, Lu Xu, Hui-min Lei, Ke-Ren Zhang, Rui Zhang, Guanglei Zhuang, Liang Zhu, Hong-zhuan Chen, Lu Zhou, Ying Shen
-
Nanocarriers overcoming biological barriers induced by multidrug resistance of chemotherapeutics in 2D and 3D cancer models Drug Resist. Updat. (IF 24.3) Pub Date : 2023-03-12 Vilma Petrikaite, Nicola D'Avanzo, Christian Celia, Massimo Fresta
Multidrug resistance (MDR) is currently a big challenge in cancer therapy and limits its success in several patients. Tumors use the MDR mechanisms to colonize the host and reduce the efficacy of chemotherapeutics that are injected as single agents or combinations. MDR mechanisms are responsible for inactivation of drugs and formbiological barriers in cancer like the drug efflux pumps, aberrant extracellular
-
Synergistic antiviral activity against drug-resistant HIV-1 by naturally occurring dipeptide and A single-stranded oligonucleotide Drug Resist. Updat. (IF 24.3) Pub Date : 2023-03-04 Rafael Ceña-Diez, Anna-Lena Spetz, Anders Sönnerborg
The novel dipeptide WG-am and single-stranded oligonucleotide combination (WG-am:ssON) showed synergistic antiviral activity against HIV-1 integrase-, protease- or reverse transcriptase drug resistant isolates, with over 95% reduction. The highest selectivity indexes were for integrase resistant isolates. WG-am:ssON can be a future option for treatment of HIV drug-resistant strains.
-
Antimicrobial peptides for combating drug-resistant bacterial infections Drug Resist. Updat. (IF 24.3) Pub Date : 2023-03-01 Jiaqi Xuan, Weiguo Feng, Jiaye Wang, Ruichen Wang, Bowen Zhang, Letao Bo, Zhe-Sheng Chen, Hui Yang, Leming Sun
The problem of drug resistance due to long-term use of antibiotics has been a concern for years. As this problem grows worse, infections caused by multiple bacteria are expanding rapidly and are extremely detrimental to human health. Antimicrobial peptides (AMPs) are a good alternative to current antimicrobials with potent antimicrobial activity and unique antimicrobial mechanisms, which have advantages
-
Global population structure and genomic surveillance framework of carbapenem-resistant Salmonella enterica Drug Resist. Updat. (IF 24.3) Pub Date : 2023-02-23 Yuye Wu, Tian Jiang, Danni Bao, Meina Yue, Huiqiong Jia, Jianyong Wu, Zhi Ruan
Due to the frequent international and intercontinental transmission of multidrug-resistant bacteria, it is imperative to understand the epidemiology, phylogeography, and population structure of carbapenem-resistant Salmonella enterica (CRSE) across the globe. During the period of 2015–2022, two blaNDM-carrying S. enterica strains were recovered from 3695 Salmonella strains in four hospitals in China
-
Carbapenemase-loaded outer membrane vesicles protect Pseudomonas aeruginosa by degrading imipenem and promoting mutation of antimicrobial resistance gene Drug Resist. Updat. (IF 24.3) Pub Date : 2023-02-15 Xiaotuan Zhang, Changrui Qian, Miran Tang, Weiliang Zeng, Jingchun Kong, Cheng Fu, Chunquan Xu, Jianzhong Ye, Tieli Zhou
Aims To investigate the effect of Klebsiella pneumoniae carbapenemase (KPC)-loaded outer membrane vesicles (OMVs) in protecting Pseudomonas aeruginosa against imipenem treatment and its mechanism. Methods The OMVs of carbapenem-resistant Klebsiella pneumonia (CRKP) were isolated and purified from the supernatant of bacterial culture by using ultracentrifugation and Optiprep density gradient ultracentrifugation
-
Replacing the tropolonic methoxyl group of colchicine with methylamino increases tubulin binding affinity with improved therapeutic index and overcomes paclitaxel cross-resistance Drug Resist. Updat. (IF 24.3) Pub Date : 2023-02-13 Juanjuan Yang, Dake Song, Bingqian Li, Xiaoxiao Gao, Yuetong Wang, Xiaohu Li, Changshun Bao, Caijiao Wu, Yu Bao, Samuel Waxman, Guoliang Chen, Yongkui Jing
Aims Microtubule inhibitors are widely used in first line cancer therapy, though drug resistance often develops and causes treatment failure. Colchicine binds to tubulins and inhibits tumor growth, but is not approved for cancer therapy due to systemic toxicity. In this study, we aim to improve the therapeutic index of colchicine through structural modification. Methods The methoxyl group of the tropolonic
-
CRISPR-Cas system as a promising player against bacterial infection and antibiotic resistance Drug Resist. Updat. (IF 24.3) Pub Date : 2023-02-10 Mohammad Abavisani, Reza Khayami, Melika Hoseinzadeh, Mansoor Kodori, Prashant Kesharwani, Amirhossein Sahebkar
The phenomenon of antibiotic resistance (AR) and its increasing global trends and destructive waves concerns patients and the healthcare system. In order to combat AR, it is necessary to explore new strategies when the current antibiotics fail to be effective. Thus, knowing the resistance mechanisms and appropriate diagnosis of bacterial infections may help enhance the sensitivity and specificity of
-
PDPN positive CAFs contribute to HER2 positive breast cancer resistance to trastuzumab by inhibiting antibody-dependent NK cell-mediated cytotoxicity Drug Resist. Updat. (IF 24.3) Pub Date : 2023-02-09 Ruoxin Du, Xiangmei Zhang, Xiyan Lu, Xiangmin Ma, Xinyan Guo, Chao Shi, Xiaofei Ren, Xindi Ma, Yutong He, Yuan Gao, Yunjiang Liu
-
Regulation of cisplatin resistance in bladder cancer by epigenetic mechanisms Drug Resist. Updat. (IF 24.3) Pub Date : 2023-02-09 Fei Li, Zaosong Zheng, Wei Chen, Dongqing Li, Henghui Zhang, Yuanchao Zhu, Qixin Mo, Xinlei Zhao, Qin Fan, Fan Deng, Conghui Han, Wanlong Tan
Bladder cancer is one of the most common malignancies in the world. Cisplatin is one of the most potent and widely used anticancer drugs and has been employed in several malignancies. Cisplatin-based combination chemotherapies have become important adjuvant therapies for bladder cancer patients. Cisplatin-based treatment often results in the development of chemoresistance, leading to therapeutic failure
-
Radioiodine therapy in advanced differentiated thyroid cancer: Resistance and overcoming strategy Drug Resist. Updat. (IF 24.3) Pub Date : 2023-02-08 Yujia Liu, Jiafeng Wang, Xiaoping Hu, Zongfu Pan, Tong Xu, Jiajie Xu, Liehao Jiang, Ping Huang, Yiwen Zhang, Minghua Ge
Thyroid cancer is the most prevalent endocrine tumor and its incidence is fast-growing worldwide in recent years. Differentiated thyroid cancer (DTC) is the most common pathological subtype which is typically curable with surgery and Radioactive iodine (RAI) therapy (approximately 85%). Radioactive iodine is the first-line treatment for patients with metastatic Papillary Thyroid Cancer (PTC). However
-
Exosomal circular RNAs: A chief culprit in cancer chemotherapy resistance Drug Resist. Updat. (IF 24.3) Pub Date : 2023-02-02 Xu Guo, Congying Gao, Dong-Hua Yang, Shenglong Li
Chemotherapy is one of the primary treatments for malignant tumors. However, the acquired drug resistance hinders clinical efficacy and leads to treatment failure in most patients. Exosomes are cell-derived vesicles with a diameter of 30–150 nm carrying and delivering substances such as DNAs, RNAs, lipids, and proteins for cellular communication in tumor development. Circular RNAs (circRNAs) present
-
Loss of cancer-associated fibroblast-derived exosomal DACT3-AS1 promotes malignant transformation and ferroptosis-mediated oxaliplatin resistance in gastric cancer Drug Resist. Updat. (IF 24.3) Pub Date : 2023-01-31 Xianlin Qu, Bing Liu, Longgang Wang, Luguang Liu, Weizhu Zhao, Changlei Liu, Jishuang Ding, Siwei Zhao, Botao Xu, Hang Yu, Xiang Zhang, Jie Chai
Aims Long non-coding RNAs (lncRNAs), as one of the components of exosomes derived from cancer-associated fibroblasts (CAFs), exhibit a crucial role in the pathogenesis and chemoresistance of gastric cancer (GC). Herein, we investigated the role and mechanism of a novel lncRNA disheveled binding antagonist of beta catenin3 antisense1 (DACT3-AS1) and its involvement in GC. Methods DACT3-AS1 was identified
-
Silver-dendrimer nanocomposite as emerging therapeutics in anti-bacteria and beyond Drug Resist. Updat. (IF 24.3) Pub Date : 2023-01-29 Xiaoling Fu, Urushi Rehman, Liuya Wei, Zhe-Sheng Chen, Mohammed A.S. Abourehab, Prashant Kesharwani, Zhi-Hong Cheng
-
Deoxycytidine kinase (dCK) inhibition is synthetic lethal with BRCA2 deficiency Drug Resist. Updat. (IF 24.3) Pub Date : 2023-01-22 Laura Guantay, Cintia Garro, Sebastián Siri, María Florencia Pansa, Sonja Ghidelli-Disse, Natalia Paviolo, Ana Racca, Viviana Nicotra, Caius Radu, José Luis Bocco, Rosana Felice, Keith H. Jansson, Katja Remlinger, Alejandro Amador, Euan Stronach, Kevin Coleman, Marcel Muelbaier, Gerard Drewes, Isro Gloger, Kevin Madauss, Gastón Soria
BRCA2 is a well-established cancer driver in several human malignancies. While the remarkable success of PARP inhibitors proved the clinical potential of targeting BRCA deficiencies, the emergence of resistance mechanisms underscores the importance of seeking novel Synthetic Lethal (SL) targets for future drug development efforts. In this work, we performed a BRCA2-centric SL screen with a collection
-
CPSF6-mediated XBP1 3’UTR shortening attenuates cisplatin-induced ER stress and elevates chemo-resistance in lung adenocarcinoma Drug Resist. Updat. (IF 24.3) Pub Date : 2023-01-25 Chuandong Zhu, Yufeng Xie, Qiang Li, Zhiwei Zhang, Juan Chen, Kai Zhang, Xuefeng Xia, Danlei Yu, Dongqin Chen, Zhengyuan Yu, Jing Chen
-
Mapping cryptic binding sites of drug targets to overcome drug resistance Drug Resist. Updat. (IF 24.3) Pub Date : 2023-01-23 Yang-Yang Gao, Wei-Cheng Yang, Charles R. Ashby, Ge-Fei Hao
The emergence of drug resistance is a primary obstacle for successful chemotherapy. Drugs that target cryptic binding sites (CBSs) represent a novel strategy for overcoming drug resistance. In this short communication, we explain and discuss how the discovery of CBSs and their inhibitors can overcome drug resistance.
-
Hallmarks of anticancer and antimicrobial activities of corroles Drug Resist. Updat. (IF 24.3) Pub Date : 2023-01-21 Vinay K. Sharma, Yehuda G. Assaraf, Zeev Gross
Corroles provide a remarkable opportunity for the development of cancer theranostic agents among other porphyrinoids. While most transition metal corrole complexes are only therapeutic, post-transition metallocorroles also find their applications in bioimaging. Moreover, corroles exhibit excellent photo-physicochemical properties, which can be harnessed for antitumor and antimicrobial interventions
-
FOXK2 affects cancer cell response to chemotherapy by promoting nucleotide de novo synthesis Drug Resist. Updat. (IF 24.3) Pub Date : 2023-01-16 Yingge Li, Jie Chen, Bin Wang, Ziwen Xu, Ci Wu, Junfeng Ma, Qibin Song, Qing Geng, Jinming Yu, Huadong Pei, Yi Yao
Aims Nucleotide de novo synthesis is essential to cell growth and survival, and its dysregulation leads to cancers and drug resistance. However, how this pathway is dysregulated in cancer has not been well clarified. This study aimed to identify the regulatory mechanisms of nucleotide de novo synthesis and drug resistance. Methods By combining the ChIP-Seq data from the Cistrome Data Browser, RNA sequencing
-
Thiol oxidative stress-dependent degradation of transglutaminase2 via protein S-glutathionylation sensitizes 5-fluorouracil therapy in 5-fluorouracil-resistant colorectal cancer cells Drug Resist. Updat. (IF 24.3) Pub Date : 2023-01-20 Xia Li, Yan Ma, Junzhou Wu, Maowei Ni, Aiping Chen, Yun Zhou, Wumin Dai, Zhongjian Chen, Ruibin Jiang, Yutian Ling, Qinghua Yao, Wei Chen
-
Sunitinib resistance in renal cell carcinoma: From molecular mechanisms to predictive biomarkers Drug Resist. Updat. (IF 24.3) Pub Date : 2023-01-17 Juan Jin, Yuhao Xie, Jin-Shi Zhang, Jing-Quan Wang, Shi-Jie Dai, Wen-fang He, Shou-Ye Li, Charles R. Ashby, Zhe-Sheng Chen, Qiang He
Currently, renal cell carcinoma (RCC) is the most prevalent type of kidney cancer. Targeted therapy has replaced radiation therapy and chemotherapy as the main treatment option for RCC due to the lack of significant efficacy with these conventional therapeutic regimens. Sunitinib, a drug used to treat gastrointestinal tumors and renal cell carcinoma, inhibits the tyrosine kinase activity of a number
-
Aeromonas spp. from hospital sewage act as a reservoir of genes resistant to last-line antibiotics Drug Resist. Updat. (IF 24.3) Pub Date : 2023-01-11 Yuchen Wu, Ning Dong, Chang Cai, Yu Zeng, Jiayue Lu, Congcong Liu, Hanyu Wang, Yanyan Zhang, Ling Huang, Weishuai Zhai, Dongyan Shao, Ruichao Li, Dejun Liu, Sheng Chen, Rong Zhang
Background Aeromonas species are opportunistic pathogens distributed widely in the ecosystem. They are known to be capable of acquiring antibiotic resistance genes, including those encoding proteins against last-line antibiotics, such as the tmexCD-toprJ, mcr and carbapenemase genes. We investigated the genomic and phenotypic characteristics of tmexCD-toprJ-positive Aeromonas strains collected from
-
CRISPR screening reveals gleason score and castration resistance related oncodriver ring finger protein 19 A (RNF19A) in prostate cancer Drug Resist. Updat. (IF 24.3) Pub Date : 2023-01-03 Ning Zhang, Da Huang, Xiaohao Ruan, Ada Tsui-Lin Ng, James Hok-Leung Tsu, Guangliang Jiang, Jingyi Huang, Yongle Zhan, Rong Na
Prostate cancer (PCa) is one of the most lethal causes of cancer-related death in male. It is characterized by chromosomal instability and disturbed signaling transduction. E3 ubiquitin ligases are well-recognized as mediators leading to genomic alterations and malignant phenotypes. There is a lack of systematic study on novel oncodrivers with genomic and clinical significance in PCa. In this study
-
Characterization difference of typical KL1, KL2 and ST11-KL64 hypervirulent and carbapenem-resistant Klebsiella pneumoniae Drug Resist. Updat. (IF 24.3) Pub Date : 2023-01-03 Ying Zhou, Chunyang Wu, Bingjie Wang, YanLei Xu, Huilin Zhao, Yinjuan Guo, Xiaocui Wu, Jingyi Yu, Lulin Rao, Xinyi Wang, Fangyou Yu
Almost all the formation of hypervirulent and carbapenem-resistant Klebsiella pneumoniae follow two major patterns: KL1/KL2 hvKP strains acquire carbapenem-resistance plasmids (CR-hvKP), and carbapenem-resistant Klebsiella pneumoniae (CRKP) strains obtain virulence plasmids (hv-CRKP). These two patterns may pose different phenotypes. In this study, three typical resistance and hypervirulent K. pneumoniae
-
Enzymatic bionanocatalysts for combating peri-implant biofilm infections by specific heat-amplified chemodynamic therapy and innate immunomodulation Drug Resist. Updat. (IF 24.3) Pub Date : 2023-01-02 Zheng Su, Lingtong Kong, Jiawei Mei, Qianming Li, Zhengzheng Qian, Yuanyuan Ma, Yue Chen, Shenghong Ju, Jiaxing Wang, Weitao Jia, Chen Zhu, Wenpei Fan
Bacterial biofilm-associated infection is a life-threatening emergency contributing from drug resistance and immune escape. Herein, a novel non-antibiotic strategy based on the synergy of bionanocatalysts-driven heat-amplified chemodynamic therapy (CDT) and innate immunomodulation is proposed for specific biofilm elimination by the smart design of a biofilm microenvironment (BME)-responsive double-layered
-
Overcoming cancer chemotherapy resistance by the induction of ferroptosis Drug Resist. Updat. (IF 24.3) Pub Date : 2022-12-29 Yumin Wang, Xiaorui Wu, Zhao Ren, Yulin Li, Wailong Zou, Jichao Chen, Hongquan Wang
Development of resistance to chemotherapy in cancer continues to be a major challenge in cancer management. Ferroptosis, a unique type of cell death, is mechanistically and morphologically different from other forms of cell death. Ferroptosis plays a pivotal role in inhibiting tumour growth and has presented new opportunities for treatment of chemotherapy-insensitive tumours in recent years. Emerging
-
Acquired non-thermal plasma resistance mediates a shift towards aerobic glycolysis and ferroptotic cell death in melanoma Drug Resist. Updat. (IF 24.3) Pub Date : 2022-12-29 Abraham Lin, Maxime Sahun, Eline Biscop, Hanne Verswyvel, Jorrit De Waele, Joey De Backer, Claudia Theys, Bart Cuypers, Kris Laukens, Wim Vanden Berghe, Evelien Smits, Annemie Bogaerts
Aims To gain insights into the underlying mechanisms of NTP therapy sensitivity and resistance, using the first-ever NTP-resistant cell line derived from sensitive melanoma cells (A375). Methods Melanoma cells were exposed to NTP and re-cultured for 12 consecutive weeks before evaluation against the parental control cells. Whole transcriptome sequencing analysis was performed to identify differentially
-
Exosomal LOC85009 inhibits docetaxel resistance in lung adenocarcinoma through regulating ATG5-induced autophagy Drug Resist. Updat. (IF 24.3) Pub Date : 2022-12-26 Zhengyuan Yu, Hailin Tang, Shaomu Chen, Yufeng Xie, Liyan Shi, Shuhua Xia, Min Jiang, Jiaoyang Li, Dongqin Chen
-
CHD4 promotes acquired chemoresistance and tumor progression by activating the MEK/ERK axis Drug Resist. Updat. (IF 24.3) Pub Date : 2022-12-26 Jing Wu, Zhijun Zhou, Jin Li, Huifang Liu, Huaqi Zhang, Junchang Zhang, Weibin Huang, Yulong He, Shiyu Zhu, Mingyu Huo, Mingyang Liu, Changhua Zhang
Aims Chemoresistance remains a major challenge in gastric cancer (GC). Chromodomain helicase DNA-binding protein 4 (CHD4) mediated chromatin remodeling plays critical roles in various tumor types, but its role in chemoresistance in GC remains uncharacterized. Methods CHD4 expression was examined by immunohistochemistry and Western blotting. The role of CHD4 on cell proliferation and chemoresistance
-
Evolution of RND efflux pumps in the development of a successful pathogen Drug Resist. Updat. (IF 24.3) Pub Date : 2022-12-23 Varsha Naidu, Amelia Bartczak, Anthony J. Brzoska, Peter Lewis, Bart A. Eijkelkamp, Ian T. Paulsen, Liam D.H. Elbourne, Karl A. Hassan
Aims This study examined the origins and evolution of the AdeABC, AdeFGH and AdeIJK efflux pumps in the Acinetobacter genus, including human and animal pathogens and species from non-clinical environments. Methods Comparative genome analyses were performed using the reference sequences for 70 Acinetobacter species to identify putative orthologs of AdeABC, AdeFGH and AdeIJK and their regulators. Sequence
-
The c-MYC-WDR43 signalling axis promotes chemoresistance and tumour growth in colorectal cancer by inhibiting p53 activity Drug Resist. Updat. (IF 24.3) Pub Date : 2022-12-13 Yuqin Di, Xiaoqian Jing, Kunhua Hu, Xiangqiong Wen, Lvlan Ye, Xiang Zhang, Jiale Qin, Jinning Ye, Run Lin, Ziyang Wang, Weiling He
Oxaliplatin chemoresistance is a major challenge in the clinical treatment of colorectal cancer (CRC), which is one of the most common malignancies worldwide. In this study, we identified the tryptophan-aspartate repeat domain 43 (WDR43) as a potentially critical oncogenic factor in CRC pathogenesis through bioinformatics analysis. It was found that WDR43 is highly expressed in CRC tissues, and WDR43